Oncopeptides has, together with HealthCap and Industrifonden (together the “Main Shareholders”), decided to, in order to further the company’s continued development of its product candidate Ygalo, carry out a broadening of its shareholder base through a new share issue of SEK 650 million (the “Offering”).
The Board of Directors of Oncopeptides has applied for a listing of the company’s shares on Nasdaq Stockholm. Gladiator, SEB-Stiftelsen and Carnegie Asset Management (together the “Cornerstone Investors”) have undertaken to, subject to certain conditions, acquire shares in the Offering for a total value of SEK 196 million. Furthermore, the Main Shareholders have undertaken to, subject to certain conditions, acquire shares in the Offering for a total value of SEK 40 million. In connection with the Offering, the company will also issue new shares as a result of the conversion of the company’s bridge loans.
Nasdaq Stockholm has approved the application subject to customary conditions. First day of trading in the company’s shares is expected to be February 22, 2017. Today the company publishes a prospectus, the price and other terms of the offering.
